Profile: Northwest Biotherapeutics Inc (NWBO.OQ)

NWBO.OQ on NASDAQ Stock Exchange Capital Market

5.45USD
19 Sep 2014
Price Change (% chg)

$-0.22 (-3.88%)
Prev Close
$5.67
Open
$5.67
Day's High
$5.69
Day's Low
$5.36
Volume
248,358
Avg. Vol
174,950
52-wk High
$10.60
52-wk Low
$3.10

Search Stocks

Northwest Biotherapeutics, Inc., incorporated in July 1998, is a development-stage company. The Company focuses on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company's approach in developing cancer therapies utilizes its capability in the biology of dendritic cells (DC), which are a type of white blood cells that activate the immune system. It focused on advancing a dendritic cell immunotherapy for prostate and brain cancer. The Company has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which it calls DCVax, and monoclonal antibodies for cancer therapeutics. Its DCVax dendritic cell-based cancer vaccine program is its main technology platform.

The Company's technology, DCVax, is a personalized immune therapy, a therapeutic vaccine that uses a patient's own dendritic cells (DCs), the master cells of the immune system, as the therapeutic agent. The patient’s DCs are obtained through a blood draw (leukapheresis). The DCs are then activated and loaded with biomarkers (antigens) from the patient’s own tumor. The Company has developed product lines based on the DCVax technology, which include the immune cells (dendritic cells) and the cancer biomarkers (antigens).

DCVax product -DCVax-L is made with cancer antigens from tumor lysate (a processed cell mixture) from the patient’s own tumor tissue. DCVax product is used in the Company’s brain cancer and ovarian cancer clinical trials. DCVax-Direct is designed for situations in which it is not feasible or not desirable for patients to have their tumors surgically removed. This includes situations in which patients have multiple metastases, or have cancers that are relatively accessible for injections, such as head and neck, liver and pancreatic cancers. DCVax-Prostate is designed specifically for late stage, hormone independent prostate cancer. Such cancer involves the spread of micro-metastases beyond the prostate tissue.

Company Address

Northwest Biotherapeutics Inc

Suite 800, 4800 Montgomery Lane
BETHESDA   MD   20814
P: +1240.4979024
F: +1302.6365454

Search Stocks